Evaxion announced new biomarker data from its phase 2 trial of the personalized cancer vaccine EVX-01 in advanced melanoma patients, demonstrating strong immune responses and validating its AI-Immunology™ platform. The data show detection of neoantigen-specific T cells directly ex vivo, with 89% vaccine target precision and sustained T-cell and clinical responses at three years. The vaccine, combined initially with pembrolizumab, achieved a 75% objective response rate, including complete responses in some patients. These findings highlight EVX-01's potential as a tailored immunotherapy and will be presented at the SITC 2026 Annual Meeting.
The new phase 2 data on the personalized cancer vaccine EVX-01 provide context for health sector market activity. For readers following health stocks, 68 of 150 priced US health-sector stocks rose while 82 fell. Notable movers include XRAY at USD 9.42 with a -6.64% change, MRVI at USD 7.44 with a +6.59% change, and NVAX at USD 10.38 with a +6.13% change and balanced buy/sell activity. This data is as of Nov 06, 2026 22:11 WIB.
The Europe portable washing machine market is projected to grow from $2.52 billion in 2025 to $3.58 billion by 2034, with a CAGR of 3.98%. Growth is fueled by urban compact living, rising demand for space-saving appliances, increased consumer mobilit...
Food Lion has agreed to purchase five Winn-Dixie stores in Southern Georgia, expanding its presence to 51 stores in the state. This acquisition will bring Food Lion's total new store openings in 2026 to 15, exceeding its original target of 10. The st...
Cerebras Systems' stock fell 19.6% on June 24, 2026, after missing Q1 earnings estimates and revealing increased costs from renting third-party capacity. A subsequent report in October questioned the durability of Cerebras' chips and alleged inflated...
The global medical imaging workstations market is projected to grow from USD 6.20 billion in 2026 to USD 12.55 billion by 2036, at a CAGR of 7.3%. Growth is fueled by rising chronic disease prevalence, increased diagnostic imaging demand, and advance...
The global sacral neuromodulation market is projected to grow from $1.37 billion in 2026 to $3.92 billion by 2036, at an 11.1% CAGR. Growth is fueled by rising cases of urinary and fecal incontinence, demand for minimally invasive treatments, and an ...
